Number 2

UNDERSEA & HYPERBARIC MEDICINE Controlled CMS Data Demonstrates a Cost and Clinical Advantage for Hyperbaric Oxygen for Radiation Cystitis John J. Feldmeier, DO1; John P. Kirby, MD2; Helen B. Gelly, MD3; Marc Robins, DO4; John Peters, FACHE5; Peter Gruhn, MA6; Sarmistha Pal, PhD6 1 Professor Emeritus and Past Chairman, Radiation Oncology, University of Toledo Medical Center 2 Associate Professor of Surgery, Washington University School of Medicine, St Louis, MO 3 President, Regenerative and Hyperbaric Medicine, Marietta, Georgia 4 Senior Medical Director, Intermountain Health 5 Executive Director, Undersea and Hyperbaric Medical Society 6 Dobson DaVanzo and Associates, LLC CORRESPONDING AUTHOR: John J. Feldmeier – jfeldmeier@aol.com ABSTRACT Feldmeier J, Kirby J, Gelly H, Robins M, Peters J, Gruhn P, Pal S. Controlled CMS Data Demonstrates a Cost and Clinical Advantage for Hyperbaric Oxygen for Radiation Cystitis. Undersea Hyperb Med. 2024 Second Quarter; 51(2):145-157. Introduction: Increasing cancer survivorship, in part due to new radiation treatments, has created a larger population at risk for delayed complications of treatment. Radiation cystitis continues to occur despite targeted radiation techniques. Materials and Methods: To investigate value-based care applying hyperbaric oxygen (HBO2) to treat delayed radiation cystitis, we reviewed public-access Medicare data from 3,309 patients from Oct 1, 2014, through Dec 31, 2019. Using novel statistical modeling, we ..

Trends in Medicare Costs of Hyperbaric Oxygen Therapy, 2013 through 2022Helen B. Gelly, MD1; Caroline E. Fife, MD2,3; David Walker, CHT2; Kristen Allison Eckert, MPhil4 1 Regenerative and Hyperbaric Medicine, Marietta, GA 2 Intellicure, Inc., The Woodlands, TX3 Baylor College of Medicine, Houston, TX4 Strategic Solutions, Inc., Bozeman, MT CORRESPONDING AUTHOR: Helen B. Gelly – helengelly@gmail.com https://www.uhms.org/b075e18e-9d75-41f0-b7be-1897776e0d5b" alt="page1image61908832" width="74.335000" height="74.333900" /> ABSTRACT Gelly H, Fife C, Walker D, Eckert K. Trends in Medicare Costs of Hyperbaric Oxygen Therapy, 2013 through 2022. Undersea Hyperb Med. 2024 Second Quarter; 51(2):137-144. Objective: To analyze Hyperbaric Oxygen Therapy Registry (HBOTR) data to estimatethe Medicare costs of hyperbaric oxygen therapy (HBO2) based on standard treatment protocols and the annual mean number of treatments per patient reported by the registry. Methods: We performed a secondary analysis of deidentified data for all payers from 53 centers registered in the HBOTR from 2013 to 2022. We estimated the mean annual per-patient costs of HBO2 based on Medicare (outpatient facility + physician) reimbursement fees adjusted to 2022 inflation using the Medicare Economic Index. Costs were calculated for the annual average number of treatments patients received each year and for a standard 40-treatment series. We estimated the 2022 costs of standard treatment protocols for HBO2 indications treated in the outpatient setting. Results: Generally, all costs decreased from ..